Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Published byAgatha Wilkins Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and."— Presentation transcript:

1 Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA2 mutation carriers. Both diagrams from Antoniou et al [3] From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

2 Figure 2. A high-risk family.
From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

3 Figure 3. The normal cells of BRCA carriers carry one normal copy and one mutated copy of the BRCA gene. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

4 Figure 4. Tumour cells in BRCA carriers have no normal copies of the BRCA gene, and are therefore BRCA deficient. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

5 Figure 5. The multi-step model of carcinogenesis allows for loss of tumour suppressor genes playing an important role in the process. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

6 Figure 6. Initial Clinical Positioning of the BCtect® test in the UK private sector as agreed by the BCtect® UK strategy group. From: Genetic counselling for hereditary predisposition to ovarian and breast cancer Ann Oncol. 2010;21(suppl_7):vii334-vii338. doi: /annonc/mdq365 Ann Oncol | © The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please

Download ppt "Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and."

Similar presentations

How to manage suspected cancer

How to manage suspected cancer
Osteoporosis therapy: an example of putting evidence- based medicine into clinical practice by D.J. Hosking, P. Geusens, and R. Rizzoli QJM Volume 98(6):403-413.

Osteoporosis therapy: an example of putting evidence- based medicine into clinical practice by D.J. Hosking, P. Geusens, and R. Rizzoli QJM Volume 98(6):
Emergencies in hereditary haemorrhagic telangiectasia by M. Gallitelli, G. Pasculli, T. Fiore, A. Carella, and C. Sabbà QJM Volume 99(1):15-22 December.

Emergencies in hereditary haemorrhagic telangiectasia by M. Gallitelli, G. Pasculli, T. Fiore, A. Carella, and C. Sabbà QJM Volume 99(1):15-22 December.
Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.

Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.
Godoy & Godoy technique of cervical stimulation in the reduction of edema of the face after cancer treatment by José Maria Pereira de Godoy, Maria de Fátima.

Godoy & Godoy technique of cervical stimulation in the reduction of edema of the face after cancer treatment by José Maria Pereira de Godoy, Maria de Fátima.
Cancer cachexia by J.N. Gordon, S.R. Green, and P.M. Goggin QJM Volume 98(11):779-788 October 17, 2005 © The Author 2005. Published by Oxford University.

Cancer cachexia by J.N. Gordon, S.R. Green, and P.M. Goggin QJM Volume 98(11): October 17, 2005 © The Author Published by Oxford University.
Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,

Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis by Tuula A. Paajanen, Niku K.J. Oksala,
Lower incisor intrusion with intraoral transosseous stainless steel wire anchorage in rabbits by Jian-chao Wu, Ji-na Huang, and Xin-ping Lin Eur J Orthod.

Lower incisor intrusion with intraoral transosseous stainless steel wire anchorage in rabbits by Jian-chao Wu, Ji-na Huang, and Xin-ping Lin Eur J Orthod.
Disorders of cognitive and affective development in cerebellar malformations by Alessandro Tavano, Rita Grasso, Chiara Gagliardi, Fabio Triulzi, Nereo.

Disorders of cognitive and affective development in cerebellar malformations by Alessandro Tavano, Rita Grasso, Chiara Gagliardi, Fabio Triulzi, Nereo.
From: A Regularist Approach to Mechanistic Type-Level Explanation

From: A Regularist Approach to Mechanistic Type-Level Explanation
From: Global Banking: Recent Developments and Insights from Research*

From: Global Banking: Recent Developments and Insights from Research*
Figure 2. Quality of life (QOL) scores for functional scale items

Figure 2. Quality of life (QOL) scores for functional scale items
Figure 3. Day 2 cell symmetry

Figure 3. Day 2 cell symmetry
Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.
Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.
Figure 2. CONSORT flow diagram.

Figure 2. CONSORT flow diagram.
Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Figure 1 Individual Lifted from Group Photograph

Figure 1 Individual Lifted from Group Photograph
Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Similar presentations

Ads by Google